Investor Relations

Corporate Profile

Urovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions.

Our lead product candidate is vibegron, an oral, once-daily, small molecule beta-3 agonist, being developed for overactive bladder (OAB), OAB in men with benign prostatic hyperplasia (BPH) and pain associated with irritable bowel syndrome (IBS).

We are currently evaluating vibegron in a pivotal Phase 3 international clinical trial for the treatment of OAB. We also plan to commence a Phase 3 clinical trial for OAB in men with BPH and a Phase 2a clinical trial for IBS-associated pain by the end of 2018. We intend to continue to expand our pipeline with the goal of creating a leading urology company by developing, commercializing and acquiring innovative therapies.

Urovant’s second investigational product candidate, URO-902, is a novel gene therapy for patients with overactive bladder (OAB) symptoms who have failed oral pharmacologic therapy.

Copyright West LLC. Minimum 15 minutes delayed.

News Releases
September 24, 2019
Urovant Sciences Reports Positive Long-Term Data from the Double-Blind Extension of the Phase 3 EMPOWUR Study of Vibegron in Patients with Overactive Bladder
    Vibegron further improved treatment benefit on key overactive bladder (OAB) symptoms over the 40-week extension period       41% of patients on vibegron became “dry,” defined as having no urge urinary incontinence episodes at week 52       Vibegron demonstrated a favorable long-term safety and
Additional Formats
September 6, 2019
Urovant Sciences Parent Company, Roivant Sciences, and Sumitomo Dainippon Pharma Enter into a Memorandum of Understanding to Create Broad Strategic Alliance
Sumitomo Dainippon Pharma is expected to fully assume Roivant’s ownership interest of Urovant Sciences (approximately 75% of outstanding Urovant shares); definitive agreement expected by the end of October 2019 Sumitomo Dainippon Pharma is a top-ten Japanese listed multi-national pharmaceutical
Additional Formats
August 13, 2019
Urovant Sciences Reports 2019 First Fiscal Quarter Financial Results
IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)--Aug. 13, 2019-- Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today reported financial results for the 2019 first fiscal
Additional Formats
Events